814P - A phase IB clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Clinical research
Renal Cell Cancer
Basic Scientific Principles
Presenter Ana Molina
Authors A.M. Molina1, T. Hutson2, J. Larkin3, A. Gold4, C. Andresen4, K. Wood5, R.J. Motzer6, M.D. Michaelson7
  • 1Genitourinary, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2Gu Oncology Program, Baylor Sammons Cancer Center, Dallas/US
  • 3Department Of Medicine, Royal Marsden Hospital, SW3 6JJ - London/UK
  • 4Pcu, Eisai Inc, Woodcliff Lake/US
  • 5Oncology Pcu, Eisai Ltd, Hatfield/UK
  • 6Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 7Medical Oncology, Massachusetts General Hospital Cancer Center, 02114 - Boston/US



Lenvatinib (L) is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR 1-4, RET, KIT, and PDGF�. Everolimus (E) is an oral mTOR inhibitor approved for RCC. This Phase (Ph) 1b/2 study investigates the combination of L plus E in RCC patients (pts) (NCT01136733). The Ph 1b component reported here assessed safety, tolerability, and maximum tolerated dose (MTD). The 3-arm randomised Ph 2 comparing PFS of L plus E and L alone versus E alone is ongoing.


Pts with advanced unresectable or metastatic RCC, ECOG PS 0-1, age ≥18 y were eligible for Ph 1b. Pts received L plus E, daily, in 28-day cycles. A standard 3 + 3 dose-escalation design with expansion cohort was used to identify the MTD.


20 pts (M/F: 14/6; median age: 59 y [range 46-72]; median of 2 prior therapeutic regimens [range 0-5]; 17/20 pts [85%] had received prior anti-VEGF treatment (tx); 7/20 pts [35%] had also received prior mTOR-targeted tx) were treated at 3 dose levels of L (12 mg [n = 7]; 18 mg [n = 11]; 24 mg [n = 2]) in combination with E 5 mg. 4 DLTs were observed: G3 nausea and vomiting (1 pt) and G2 mucositis (1 pt) at 24 mg; G3 elevated CPK at 18 mg; G3 abdominal pain at 12 mg. The MTD was L 18 mg plus E 5 mg. Median duration of tx was 14.5 wk (range 1-68, 7/20 (35%) pts ongoing). The most common tx-related adverse events (AEs), all grades were fatigue 45% (G3, 5%); mucosal inflammation 40%; proteinuria 35% (G3, 10%); diarrhoea 30% (G3, 5%); rash 30%; hypertension 25%; nausea, vomiting each 25% (each G3 5%); constipation, decreased appetite, epistaxis each 20%. There was 1 G4 related AE of hypercholesterolemia. PR was observed in 6/18 (33%) pts in the MTD and lower dosing cohorts. Durable stable disease (≥23 wk) or PR were achieved in 8/16 (50%) pts with postbaseline tumor assessments (and 3 pts ongoing with SD <23 wk at time of data cut). Median PFS is 7.2 mos at MTD and lower dosing cohort.


Lenvatinib 18 mg in combination with everolimus 5 mg appeared to be safe when administered to multiply pretreated patients with advanced RCC in this Ph 1b part. The PRs observed and response durability warrant further evaluation in this refractory population during the ongoing Ph 2 part of the study.


A.M. Molina: A. Molina discloses research funding from EISAI and Novartis.

J. Larkin: J. Larkin has received honoraria from EISAI.

A. Gold: A. Gold is an employee of Eisai, Inc.

C. Andresen: C. Andresen is an employee of Eisai, Inc.

K. Wood: K. Wood is an employee of EISAI, Ltd.

R.J. Motzer: R. Motzer discloses research funding from EISAI and Novartis, both >$10,000.

M.D. Michaelson: Dr. Michaelson discloses institutional research funding from: EISAI, Pfizer, Abbott, GlaxoSmithKline, Genentech Consultant or advisory role (UNCOMPENSATED): Pfizer, EISAI.

All other authors have declared no conflicts of interest.